All Stories

  1. Dialysis Recovery Time—Can We Do Better?
  2. The impact of obesity on body surface area adjusted estimated glomerular filtration rate in patients with chronic kidney disease
  3. Clinical Adjudication of Hemodialysis Catheter-Related Bloodstream Infections: Findings from the REDUCCTION Trial
  4. Comparison of Residual Kidney Function Assessment Between the Hemodialysis 2-Day and 3-Day Interdialytic Interval
  5. Oral Anticoagulant Use in Patients With Atrial Fibrillation and Chronic Kidney Disease: A Review of the Evidence With Recommendations for Australian Clinical Practice
  6. CKD—Where Have All the Women Gone?
  7. Cost-Effectiveness of Targeted Exome Analysis as a Diagnostic Test in Glomerular Diseases
  8. Home and facility haemodialysis patients: a comparison of outcomes in a matched cohort
  9. Response to COVID-19 Infection in Hemodialysis Patients: An Australian Perspective
  10. Home based therapies: can wishes be realized?
  11. Updates on baseline characteristics of the omega-3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study
  12. Self-management in patients with diabetes and chronic kidney disease is associated with incremental benefit in HRQOL
  13. The effect of holiday haemodialysis treatments on patient mood, adverse symptoms and subjective wellbeing using the Big Red Kidney Bus
  14. Predictors of Health-Related Quality of Life in Patients with Co-Morbid Diabetes and Chronic Kidney Disease
  15. Reliability and validity of the coping strategy inventory-short form applied to hemodialysis patients in 13 countries: Results from the Dialysis Outcomes and Practice Patterns Study (DOPPS)
  16. Conservative care in ESRD
  17. Allogeneic Mesenchymal Precursor Cells (MPC) in Diabetic Nephropathy: A Randomized, Placebo-controlled, Dose Escalation Study
  18. Patient and Caregiver Priorities for Outcomes in Hemodialysis: An International Nominal Group Technique Study
  19. Factors affecting outcomes in patients reaching end-stage kidney disease worldwide: differences in access to renal replacement therapy, modality use, and haemodialysis practices
  20. Primary and tertiary health professionals’ views on the health-care of patients with co-morbid diabetes and chronic kidney disease – a qualitative study
  21. Keeping Home Dialysis Patients at Home
  22. Deferasirox at therapeutic doses is associated with dose-dependent hypercalciuria
  23. Intensive Hemodialysis and Mortality Risk in Australian and New Zealand Populations
  24. How much is enough? An investigation of the relationship between haemodialysis adequacy and quality of life of elderly patients
  25. Human mesenchymal stem cells alter the gene profile of monocytes from patients with Type 2 diabetes and end-stage renal disease
  26. Human podocyte depletion in association with older age and hypertension
  27. The Perspectives of Patients on Health-Care for Co-Morbid Diabetes and Chronic Kidney Disease: A Qualitative Study
  28. Temporal Changes in Mortality Risk by Dialysis Modality in the Australian and New Zealand Dialysis Population
  29. Standardised outcomes in nephrology – Haemodialysis (SONG-HD): study protocol for establishing a core outcome set in haemodialysis
  30. Research Priorities in CKD: Report of a National Workshop Conducted in Australia
  31. Podocyte Number in Children and Adults: Associations with Glomerular Size and Numbers of Other Glomerular Resident Cells
  32. Thalassemia Bone Disease: A 19-Year Longitudinal Analysis
  33. High rates of death and hospitalization follow bone fracture among hemodialysis patients
  34. Editorial
  35. Review: Membranes for haemodialysis
  36. Introduction
  37. Handbook of Dialysis Therapy
  38. ARTERIAL CALCIFICATION AND STIFFNESS IN CHRONIC KIDNEY DISEASE
  39. High-flux dialysers*
  40. ASSESSMENT OF PLATELET FUNCTION IN HAEMODIALYSIS PATIENTS
  41. NOVEL ERYTHROPOIESIS STIMULATING PROTEIN (NESP) MAINTAINS HAEMOGLOBIN IN ESRD PATIENTS WHEN ADMINISTERED ONCE WEEKLY OR ONCE EVERY OTHER WEEK
  42. Deoxyspergualin inhibits cytotoxic T lymphocytes but not NK or LAK cells